Lucy Oldfield
YOU?
Author Swipe
View article: Cost-Effectiveness of Biomarker-Associated Early Pancreatic Cancer Detection in New-Onset Diabetes
Cost-Effectiveness of Biomarker-Associated Early Pancreatic Cancer Detection in New-Onset Diabetes Open
Importance Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed late, resulting in a dismal survival. Only 1 in 5 patients is eligible for potentially curative surgery. Although earlier detection of PDAC could significantly improve p…
View article: Prevalence of New-Onset Diabetes in Patients Undergoing Pancreatic Surgery and the Association of Glucose Dysregulation With Complications in Pancreatic Cancer
Prevalence of New-Onset Diabetes in Patients Undergoing Pancreatic Surgery and the Association of Glucose Dysregulation With Complications in Pancreatic Cancer Open
Objective: To determine the prevalence of new-onset diabetes (NOD) in individuals undergoing pancreatic surgery and to explore the implications of glycaemic status on clinicopathological features and outcomes for patients with pancreatic d…
View article: Transforming Anxiety, Depression, and Quality of Life in Rural Remote Workers with GAD via Music Therapy: A Quasi-Experimental Study
Transforming Anxiety, Depression, and Quality of Life in Rural Remote Workers with GAD via Music Therapy: A Quasi-Experimental Study Open
Generalized Anxiety Disorder (GAD), often accompanied by comorbid depression, poses significant challenges to mental health, particularly among remote workers in underserved rural areas. These individuals frequently face unique stressors s…
View article: Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer
Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer Open
Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed in its late stages when treatment options are limited. Unlike other common cancers, there are no population-wide screening programmes for PDAC. Thus, early disease detection, …
View article: Where the metabolome meets the microbiome for pancreatic cancer detection
Where the metabolome meets the microbiome for pancreatic cancer detection Open
View article: Supplementary Table S1. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Supplementary Table S1. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Patient Characteristics of iTRAQ sample pools.
View article: Supplementary Table S4. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Supplementary Table S4. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Comparison of TSP-1 serum levels in PDAC patients with clinicopathological parameters.
View article: Supplementary Figure S1. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Supplementary Figure S1. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
(A) Peptides unique to TSP-1 (in red) were used to quantify the protein using multiple reaction monitoring (MRM). (B) Detection of TSP-1 by western analysis in UKCTOCS and PBRU samples. Human Foreskin Fibroblast (HFF) cells treated with TS…
View article: Supplementary Table S4. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Supplementary Table S4. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Comparison of TSP-1 serum levels in PDAC patients with clinicopathological parameters.
View article: SUPPLEMENTARY DATA from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
SUPPLEMENTARY DATA from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Supplementary Legends
View article: Data from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Data from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Purpose: Identification of serum biomarkers enabling earlier diagnosis of pancreatic ductal adenocarcinoma (PDAC) could improve outcome. Serum protein profiles in patients with preclinical disease and at diagnosis were investigated.…
View article: Supplementary Table S3. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Supplementary Table S3. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Representative data from the T5600 iTRAQ serum 8-plex experiment. iTRAQ labels were used as follows: 113: 0-6m cases, 114: 0-6m controls, 115: 6-12m cases, 116: 6-12m controls, 117: PDAC non obstructed, 118: PDAC obstructed, 119: CP, 121: …
View article: Supplementary Table S2. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Supplementary Table S2. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Peptides and their fragment ions used in MRM assays for TSP-1.
View article: Supplementary Figure S1. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Supplementary Figure S1. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
(A) Peptides unique to TSP-1 (in red) were used to quantify the protein using multiple reaction monitoring (MRM). (B) Detection of TSP-1 by western analysis in UKCTOCS and PBRU samples. Human Foreskin Fibroblast (HFF) cells treated with TS…
View article: Supplementary Table S2. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Supplementary Table S2. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Peptides and their fragment ions used in MRM assays for TSP-1.
View article: Supplementary Figure S3. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Supplementary Figure S3. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Detection of CA1-9 by ELISA in (A) individual time to diagnosis groups and (B) diagnosed samples and controls.
View article: Supplementary Figure S3. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Supplementary Figure S3. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Detection of CA1-9 by ELISA in (A) individual time to diagnosis groups and (B) diagnosed samples and controls.
View article: Supplementary Table S5. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Supplementary Table S5. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Comparison of TSP-1 tissue expression in PDAC patients with clinicopathological parameters.
View article: Supplementary Figure S2. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Supplementary Figure S2. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Detection of thrombospondin 1 (TSP-1) by MRM in resectable PDAC cases versus advanced PDAC cases
View article: Data from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Data from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Purpose: Identification of serum biomarkers enabling earlier diagnosis of pancreatic ductal adenocarcinoma (PDAC) could improve outcome. Serum protein profiles in patients with preclinical disease and at diagnosis were investigated.…
View article: Supplementary Table S1. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Supplementary Table S1. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Patient Characteristics of iTRAQ sample pools.
View article: SUPPLEMENTARY DATA from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
SUPPLEMENTARY DATA from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Supplementary Legends
View article: Supplementary Table S3. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Supplementary Table S3. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Representative data from the T5600 iTRAQ serum 8-plex experiment. iTRAQ labels were used as follows: 113: 0-6m cases, 114: 0-6m controls, 115: 6-12m cases, 116: 6-12m controls, 117: PDAC non obstructed, 118: PDAC obstructed, 119: CP, 121: …
View article: Supplementary Figure S2. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Supplementary Figure S2. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Detection of thrombospondin 1 (TSP-1) by MRM in resectable PDAC cases versus advanced PDAC cases
View article: Supplementary Table S5. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Supplementary Table S5. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Comparison of TSP-1 tissue expression in PDAC patients with clinicopathological parameters.
View article: United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early detection of pancreatic cancer
United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early detection of pancreatic cancer Open
Introduction Pancreatic cancer is a leading cause of cancer deaths worldwide. Screening for this disease has potential to improve survival. It is not feasible, with current screening modalities, to screen the asymptomatic adult population.…
View article: Recent advances in understanding pancreatic cancer
Recent advances in understanding pancreatic cancer Open
Pancreatic ductal adenocarcinoma (PDAC) is an intractable cancer and a leading cause of cancer deaths worldwide. Over 90% of patients die within 1 year of diagnosis. Deaths from PDAC are increasing and it remains a cancer of substantial un…
View article: Recent advances in understanding pancreatic cancer
Recent advances in understanding pancreatic cancer Open
Pancreatic ductal adenocarcinoma (PDAC) is an intractable cancer and a leading cause of cancer deaths worldwide. Over 90% of patients die within 1 year of diagnosis. Deaths from PDAC are increasing and it remains a cancer of substantial un…
View article: Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes
Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes Open
North West Cancer Research, UK, Cancer Research UK, Pancreatic Cancer Action, UK.
View article: Oldfield et al T3cDM biomarker dataset
Oldfield et al T3cDM biomarker dataset Open
Training and validation data supporting the identification of candidate biomarkers for identification of type 3c diabetes from relevant control groups.